Related Experiment Video
Updated: Jul 26, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
[Antiretroviral pharmaceutical expenditure and possibilities for optimization]
C Tornero Estebanez1, A Cuenca Soria, A Nolasco Bonmatí
1Servicio de Medicina Interna, Hospital Francisco de Borja, Gandia, Valencia. tornero_cas@gua.es
High antiretroviral medication costs are significant for HIV treatment. A study found nearly 20% of expenditure benefits patients with ineffective treatment or dropouts, suggesting cost-saving opportunities.
Area of Science:
- Infectious Diseases
- Pharmacoeconomics
- Public Health
Context:
- Antiretroviral therapy (ART) is crucial for managing HIV/AIDS.
- Treatment compliance, drug resistance, and disease stage impact ART efficacy and costs.
- Optimizing ART expenditure is essential for healthcare systems.
Purpose:
- To analyze the distribution of antiretroviral pharmaceutical expenditure in a district hospital.
- To identify inefficiencies in ART drug spending.
- To explore possibilities for improving the cost-effectiveness of HIV treatment.
Summary:
- A 12-week prospective cohort study of 128 HIV patients analyzed antiretroviral drug costs.
- 108 patients on highly active antiretroviral therapy (HAART) incurred costs of €232,366.
- Previous treatment dropout predicted new dropouts and failures; 19.4% of expenditure was on ineffective treatments.
Impact:
- Significant antiretroviral drug costs necessitate efficiency improvements.
- Approximately 19.4% of ART expenditure may be on patients with non-beneficial treatment.
- Further consideration of ART necessity is warranted for patients with good immune status (CD4+ >350 cells/ml).
Related Concept Videos
Retrovirus Life Cycles
Retroviruses
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors

